Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLB-002 in Advanced Solid Tumors
NCT07304128Phase 1Recruiting
- Sponsor
- Primelink BioTherapeutics
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PLB-002 in solid tumor, ovarian cancer, non-small cell lung cancer (NSCLC) and 1 more, sponsored by Primelink BioTherapeutics. Primary endpoints: Recommended Extension Dose and Recommended Phase 2 Dose at 2 years and Incidence and severity of adverse events and serious adverse events at 2 years. Started Feb 2026; status: recruiting.
02
Drugs
PLB-002
03
Conditions
solid tumorovarian cancernon-small cell lung cancer (NSCLC)testicular cancer
Beyond the preview
Go deeper on NCT07304128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304128.